Clinical trial MK-3475-B96/KEYNOTE-B96/ENGOT-ov65
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTEB96/ ENGOT-ov65)
| Cancers | |
|---|---|
| Organ | Ovary |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Merck |
| EudraCT Identifier | 2020-005027-37 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05116189 |
| Last update |